277 related articles for article (PubMed ID: 25721606)
1. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.
Sengupta S; Biarnes MC; Clarke R; Jordan VC
Breast Cancer Res Treat; 2015 Apr; 150(2):265-78. PubMed ID: 25721606
[TBL] [Abstract][Full Text] [Related]
2. Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.
Murakami S; Li R; Nagari A; Chae M; Camacho CV; Kraus WL
Mol Cancer Res; 2019 Dec; 17(12):2356-2368. PubMed ID: 31551256
[TBL] [Abstract][Full Text] [Related]
3. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
4. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
5. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
7. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
10. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
[TBL] [Abstract][Full Text] [Related]
11. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
[TBL] [Abstract][Full Text] [Related]
12. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators.
Cho H; Katzenellenbogen BS
Mol Endocrinol; 1993 Mar; 7(3):441-52. PubMed ID: 7683375
[TBL] [Abstract][Full Text] [Related]
14. RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells.
Jung KH; Das A; Chai JC; Kim SH; Morya N; Park KS; Lee YS; Chai YG
J Neuroinflammation; 2015 Feb; 12():36. PubMed ID: 25890327
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain and Extraterminal Inhibition by JQ1 Produces Divergent Transcriptional Regulation of Suppressors of Cytokine Signaling Genes in Adipocytes.
Mota de Sá P; Richard AJ; Stephens JM
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31875887
[TBL] [Abstract][Full Text] [Related]
16. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
18. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
[TBL] [Abstract][Full Text] [Related]
20. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]